BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development, net | 1,120 | |||
| General and administrative | 1,453 | |||
| Operating loss | -2,573 | |||
| Financial income (expense), net | -330 | |||
| Net loss | -2,903 | |||
| Earnings per share, basic | -0.34 | |||
| Earnings per share, diluted | -0.34 | |||
| Weighted average number of shares outstanding, basic | 8,620,400 | |||
| Weighted average number of shares outstanding, diluted | 8,620,400 | |||